NON PSYCHOACTIVE CANNABINOIDS WITH THERAPEUTIC POTENTIAL
具有治疗潜力的非精神活性大麻素
基本信息
- 批准号:6378830
- 负责人:
- 金额:$ 24.58万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1999
- 资助国家:美国
- 起止时间:1999-08-11 至 2003-06-30
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
The broad goal of this application is to establish that the THC acids represent a distinct class of cannabinoids which have been reported not to bind to either of the known cannabinoid receptors. Although showing no psychotropic activity, they display certain of the pharmacological activities associated with the use of marijuana. The acids occur naturally as metabolites of THC and, as such, can be detected readily in the tissues of marijuana users. The properties of the acids, shown in experimental models, suggest that they may be of interest as candidates for medicinal agents. These include actions as analgesics and antiinflammatory drugs with a low potential for abuse and a minimum of toxic side effects. In this proposal, two approaches will be used to answer the question of whether or not the acid metabolites of THC have a role in the actions of the parent compound. First, attempts will be made to discover high affinity, saturable binding sties for the cannabinoid acids using high specific activity, radiolabelled acid derivatives. Structure-activity binding protocols to be included will be aimed at showing stereospecificity and rank orders that resemble the potencies of the acids in the various systems. Second, possible mechanisms for the antiinflammatory effects of the acids will be investigated and compared with the primary cannabinoids to look for differences as well as similarities. Experiments will be done to determine their effects on cytokines, eicosanoids and metalloproteinases in human cell culture systems. Where feasible, in vivo correlates will be examined to show relevance for all of the above studies. The findings that will be generated from this proposal might provide a possible solution to the current controversy over the medical use of marijuana. This would be accomplished by the discovery of synthetic analogs of THC, the active principal of marijuana, that would provide the medicinal benefits of Cannabis without the accompanying mood altering effects and abuse potential.
这项申请的广泛目标是确定THC酸代表一种不同类别的大麻素,据报道,这些大麻素不与任何已知的大麻素受体结合。虽然它们没有精神活性,但它们显示了与使用大麻有关的某些药理活性。这些酸是作为THC的代谢物自然产生的,因此,在大麻使用者的组织中很容易检测到。实验模型中显示的酸的性质表明,它们可能是药剂的候选药物。这些药物包括作为镇痛剂和抗炎药的作用,滥用的可能性低,毒副作用最小。在这项提案中,将使用两种方法来回答THC的酸性代谢物是否在母体化合物的作用中发挥作用的问题。首先,将尝试使用高比活性的放射性标记酸衍生物来发现高亲和力、可饱和的大麻酸结合带。将包括的结构-活性结合协议的目的是显示立体专一性和类似于各种体系中酸的势能的排列顺序。其次,将调查这些酸的抗炎作用的可能机制,并与主要的大麻素类进行比较,以寻找不同之处和相似之处。将进行实验,以确定它们对人类细胞培养系统中的细胞因子、二十烷类化合物和金属蛋白酶的影响。在可行的情况下,将检查体内的相关性,以显示与上述所有研究的相关性。这项提案将产生的结果可能会为目前关于医用大麻的争议提供一个可能的解决方案。这将通过发现大麻的有效成分THC的合成类似物来实现,它将提供大麻的药用价值,而不会伴随着情绪改变的影响和滥用的可能性。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
SUMNER HOWARD BURSTEIN其他文献
SUMNER HOWARD BURSTEIN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('SUMNER HOWARD BURSTEIN', 18)}}的其他基金
The elmiric acids: biologically active anandamide analogs.
elmiric Acids:具有生物活性的 anandamide 类似物。
- 批准号:
7727687 - 财政年份:2009
- 资助金额:
$ 24.58万 - 项目类别:
The elmiric acids: biologically active anandamide analogs.
elmiric Acids:具有生物活性的 anandamide 类似物。
- 批准号:
7894890 - 财政年份:2009
- 资助金额:
$ 24.58万 - 项目类别:
Endocannabinoid Analogs as Anti-inflammatory Agents
作为抗炎剂的内源性大麻素类似物
- 批准号:
7106374 - 财政年份:2004
- 资助金额:
$ 24.58万 - 项目类别:
Endocannabinoid Analogs as Anti-inflammatory Agents
作为抗炎剂的内源性大麻素类似物
- 批准号:
6951593 - 财政年份:2004
- 资助金额:
$ 24.58万 - 项目类别:
Endocannabinoid Analogs as Anti-inflammatory Agents
作为抗炎剂的内源性大麻素类似物
- 批准号:
6749403 - 财政年份:2004
- 资助金额:
$ 24.58万 - 项目类别:
Endocannabinoid Analogs as Anti-inflammatory Agents
作为抗炎剂的内源性大麻素类似物
- 批准号:
7678732 - 财政年份:2004
- 资助金额:
$ 24.58万 - 项目类别:
NON PSYCHOACTIVE CANNABINOIDS WITH THERAPEUTIC POTENTIAL
具有治疗潜力的非精神活性大麻素
- 批准号:
6175550 - 财政年份:1999
- 资助金额:
$ 24.58万 - 项目类别:
NON PSYCHOACTIVE CANNABINOIDS WITH THERAPEUTIC POTENTIAL
具有治疗潜力的非精神活性大麻素
- 批准号:
2902241 - 财政年份:1999
- 资助金额:
$ 24.58万 - 项目类别:
NON PSYCHOACTIVE CANNABINOIDS WITH THERAPEUTIC POTENTIAL
具有治疗潜力的非精神活性大麻素
- 批准号:
6515659 - 财政年份:1999
- 资助金额:
$ 24.58万 - 项目类别:
BIOSYNTHESIS OF ANANDAMIDE--A NOVEL EICOSANOID
新型二十烷酸阿南达胺的生物合成
- 批准号:
2122673 - 财政年份:1995
- 资助金额:
$ 24.58万 - 项目类别:
相似海外基金
Planning Study for the Development of Sigma 2 ligands as Analgesics
Sigma 2 配体镇痛药开发规划研究
- 批准号:
10641500 - 财政年份:2023
- 资助金额:
$ 24.58万 - 项目类别:
Designing and validating optimal nonaddictive analgesics using the CANDO paradigm
使用 CANDO 范式设计和验证最佳的非成瘾性镇痛药
- 批准号:
10485593 - 财政年份:2023
- 资助金额:
$ 24.58万 - 项目类别:
Identification of botanical hHv1 channel blockers as analgesics for neuropathic pain
植物 hHv1 通道阻滞剂作为神经性疼痛镇痛药的鉴定
- 批准号:
10728526 - 财政年份:2023
- 资助金额:
$ 24.58万 - 项目类别:
Development of LPA5 Antagonists as Analgesics
LPA5 拮抗剂镇痛药的开发
- 批准号:
10638278 - 财政年份:2023
- 资助金额:
$ 24.58万 - 项目类别:
Designed Multiple Ligands as Non-opioid Analgesics for Treating Chronic Pain
设计多种配体作为非阿片类镇痛药,用于治疗慢性疼痛
- 批准号:
10621646 - 财政年份:2023
- 资助金额:
$ 24.58万 - 项目类别:
Elucidation of the mechanism of pain suppression by exercise and development of new analgesics
阐明运动镇痛机制及开发新型镇痛药
- 批准号:
22K19602 - 财政年份:2022
- 资助金额:
$ 24.58万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
Single-administration microneedles with controlled sustained release of non-opioid analgesics to treat osteoarthritis pain
单次给药微针控制缓释非阿片类镇痛药治疗骨关节炎疼痛
- 批准号:
10425794 - 财政年份:2022
- 资助金额:
$ 24.58万 - 项目类别:
Allosteric Targeting of Cannabinoid CB1 Receptor to Develop Non-Addictive Small Molecule Analgesics
大麻素 CB1 受体变构靶向开发非成瘾性小分子镇痛药
- 批准号:
10512672 - 财政年份:2022
- 资助金额:
$ 24.58万 - 项目类别:
A novel clinically-relevant mouse model of chronic overlapping pain conditions for screening analgesics
用于筛选镇痛药的新型临床相关慢性重叠疼痛小鼠模型
- 批准号:
10821681 - 财政年份:2022
- 资助金额:
$ 24.58万 - 项目类别:
Single-administration microneedles with controlled sustained release of non-opioid analgesics to treat osteoarthritis pain
单次给药微针控制缓释非阿片类镇痛药治疗骨关节炎疼痛
- 批准号:
10721752 - 财政年份:2022
- 资助金额:
$ 24.58万 - 项目类别:














{{item.name}}会员




